The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Medtronic Inc. (NYSE:MDT) won FDA clearance for its next generation iPro2 Professional continuous glucose monitor.
The iPro2 Professional is a clinician-owned device that collects glucose data from a sensor inserted into a patient’s skin.
The device tracks the patient’s glucose levels for 3 days, collecting data as many as 288 times each day. The information may provide insight into how diet, medication and daily activities affect a patient’s glucose levels.
Microcatheter maker iScience Interventional announced an investment by med-tech goliath Medtronic Inc. (NYSE:MDT) to support the commercialization of its drug delivery technologies.
The Menlo Park, Calif.-based company’s microcatheter is used during the surgical treatment of glaucoma to deliver drugs to the eye.
Biomet Inc.’s first-quarter losses widened significantly despite nearly 4 percent top-line growth during the three months ended August 31.
The privately owned orthopedics giant posted losses of $39 million on sales of $665 million during the quarter, up 120.2 percent and 3.7 percent, respectively, over Q1 2011.
After nearly a year, Sonova Holding AG (SIX:SOON) subsidary Advanced Bionics was allowed back in the U.S. market with its HiRes 90K cochlear implant.
In the past few months, Advanced Bionics received approval to resume distribution in Canada and countries accepting the CE Mark.
World’s Only Liquid Radiation Balloon Catheter Device Treats Glioblastomas and Metastasized Brain Cancers
RICHLAND, Wash.–(BUSINESS WIRE)–IsoRay, Inc. (Amex: ISR) announced today that the FDA has cleared its GliaSite® radiation therapy system, a balloon catheter device used in the treatment of brain cancer. The clearance was the major step required to return the GliaSite® radiation therapy system to the marketplace. The system’s balloon catheter is a landmark technology that allows physicians to treat more brain cancer patients than ever before with internal radiation or brachytherapy.
Cambridge Heart Inc. (OTC:CAMH) took a hit during the first quarter, as last year’s acquisition of partner Cardiac Science helped drive sales down 3.2 percent, even as it prepped an offering to raise enough cash to keep going after the end of this year.
Taris Biomedical Inc. drummed up $18.3 million in its latest funding round.
Lexington, Mass.-based company said the equity-based B round will support its lidocaine delivery technology developed at MIT to treat bladder conditions.
Third Rock Ventures, a new backer for the company, led the round, and previous investors Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners also participated in the financing.
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Isoray Inc. (AMEX:ISR) has a commitment for more than $4.3 million in financing that the company said will go towards development of three cancer treatments.
The Richland, Wash.-based firm agreed to sell $2.25 million in stock to an individual investor, with the potential of an additional $2 million in short term warrants at an average price of $1.40, according to a statement from the company.
